TORONTO, Nov. 12, 2025 /CNW/ - i-80 GOLD CORP. (TSX: IAU) (NYSE American: IAUX) ("i-80 Gold" or the "Company") reports its operating and financial results for the three and nine months ended September ...

PRNewswire/ - i-80 GOLD CORP. (TSX: IAU) (NYSE American: IAUX) ("i-80 Gold" or the "Company") reports its operating and financial results for the three and nine months ended September 30, 2025, ...

Q3 2025 Management View CEO Jean-Pierre Sommadossi reported "significant progress and achievements" this quarter, ...

Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026New preclinical data demonstrated SIL204’s ...

If you haven’t done so already, we encourage you to determine your short- and long-term career goals to identify your postdoc training needs. Creating an IDP is a great way to do this, and when you’re ...

SEP-479 Selected as Next-Generation Oral PTH1R Agonist Development CandidateSEP-631 (MRGPRX2 NAM) Phase 1 Clinical Trial in Healthy Volunteers ...

The StruXure.co platform centralizes the management of the Prime Contract, subcontracts, and purchase orders, providing ...

Q3 2025 Management View CEO Richard Miller emphasized continued progress in the development of soquelitinib for atopic ...

Request to create a README file for the OctoAcme Project Management Docs that includes: A brief summary of OctoAcme's project management processes as used in the organization. A list of links to all ...

In an effort to mitigate the threat of wildfire, crews from the Western Colorado Conservation Corps have been out thinning overgrown vegetation on a conserved property in Plateau Valley. The crews ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

WATERTOWN, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the ...